StockMirror — Stock Screener

AGARWALEYE Q2 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

Dr. Agarwal's Health Care reported strong H1 FY27 performance with revenue from operations up 28.7% YoY to INR 1,269 crores, Ind AS EBITDA up 27% to INR 362 crores (28.2% margin), and PAT up 50.1% to INR 112 crores (8.7% margin, up ~130 bps YoY). Q2 FY27 revenue grew 31.4% YoY to INR 655 crores with PAT up 55.8% to INR 57 crores. The company added a record 21 facilities in Q2 (19 greenfield + 2 acquired) and 39 in H1, and revised FY27 guidance upward to 65 facilities (55 surgical) and capex to INR 500 crores. SSSG was 18.8% in Q2 and 17.7% in H1, driven by volume (~8%) and premiumization/price (~9.5%). Key risks include startup losses from new facilities (INR 42 crores in H1) and potential regulatory intervention on device/implant margins. Management remains focused on both growth and margins, with a predominantly greenfield strategy supplemented by selective bolt-on acquisitions.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management emphasized record network expansion (65 facilities targeted, capex INR 500 crores) alongside stable EBITDA margins (~28%) despite startup losses and PAT margin expansion (~130 bps YoY), indicating balanced focus on growth and profitability.

About Dr. Agarwal's Health Care Limited

Dr. Agarwal's Health Care Limited (AGARWALEYE) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More